Literature DB >> 24299555

Interferon-γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States.

Susan E Dorman1, Robert Belknap, Edward A Graviss, Randall Reves, Neil Schluger, Paul Weinfurter, Yaping Wang, Wendy Cronin, Yael Hirsch-Moverman, Larry D Teeter, Matthew Parker, Denise O Garrett, Charles L Daley.   

Abstract

RATIONALE: IFN-γ release assays (IGRAs) are alternatives to tuberculin skin testing (TST) for diagnosis of latent tuberculosis infection. Limited data suggest IGRAs may not perform well for serial testing of healthcare workers (HCWs).
OBJECTIVES: Determine the performance characteristics of IGRAs versus TST for serial testing of HCWs.
METHODS: A longitudinal study involving 2,563 HCWs undergoing occupational tuberculosis screening at four healthcare institutions in the United States, where the average tuberculosis case rate ranged from 4 to 9 per 100,000 persons. QuantiFERON-TB Gold In-Tube (QFT-GIT), T-SPOT.TB (T-SPOT), and TST were performed at baseline and every 6 months for 18 months between February 2008 and March 2011.
MEASUREMENTS AND MAIN RESULTS: A total of 2,418 HCWs completed baseline testing, which was positive for 125 (5.2%) by TST, 118 (4.9%) by QFT-GIT, and 144 (6.0%) by T-SPOT. A baseline positive TST with negative IGRAs was associated with bacillus Calmette-Guérin (BCG) vaccination (odds ratio: 25.1 [95% confidence interval: 15.5, 40.5] vs. no BCG). Proportions of participants with test conversion during the study period were 138 of 2,263 (6.1%) for QFT-GIT, 177 of 2,137 (8.3%) for T-SPOT, and 21 of 2,293 (0.9%) for TST (P < 0.001 for QFT-GIT vs. TST and for T-SPOT vs. TST; P = 0.005 for QFT-GIT vs. T-SPOT). Of the QFT-GIT and T-SPOT converters, 81 of 106 (76.4%) and 91 of 118 (77.1%), respectively, were negative when retested 6 months later. There was negative/positive discordance for 15 of 170 (8.8%) participants by QFT-GIT and for 19 of 151 (12.6%) by T-SPOT when blood was drawn 2 weeks later.
CONCLUSIONS: Most conversions among HCWs in low TB incidence settings appear to be false positives, and these occurred six to nine times more frequently with IGRAs than TST; repeat testing of apparent converters is warranted.

Entities:  

Mesh:

Year:  2014        PMID: 24299555     DOI: 10.1164/rccm.201302-0365OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  78 in total

Review 1.  Update in Mycobacterium tuberculosis lung disease 2014.

Authors:  Paul Elkington; Alimuddin Zumla
Journal:  Am J Respir Crit Care Med       Date:  2015-10-01       Impact factor: 21.405

2.  Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study.

Authors:  Jason R Andrews; Elisa Nemes; Michele Tameris; Bernard S Landry; Hassan Mahomed; J Bruce McClain; Helen A Fletcher; Willem A Hanekom; Robin Wood; Helen McShane; Thomas J Scriba; Mark Hatherill
Journal:  Lancet Respir Med       Date:  2017-02-16       Impact factor: 30.700

3.  Should all patients undergoing treatment with biologic agents be screened annually for latent tuberculosis infection with an interferon gamma release assay?

Authors:  M G Johnson; R W Bialas; R P Hall; J E Stout
Journal:  J Dermatolog Treat       Date:  2015-12-10       Impact factor: 3.359

Review 4.  Management of Latent Tuberculosis Infection in Children from Developing Countries.

Authors:  Agam Jain; Rakesh Lodha
Journal:  Indian J Pediatr       Date:  2019-02-11       Impact factor: 1.967

5.  The dynamics of QuantiFERON-TB gold in-tube conversion and reversion in a cohort of South African adolescents.

Authors:  Jason R Andrews; Mark Hatherill; Hassan Mahomed; Willem A Hanekom; Monica Campo; Thomas R Hawn; Robin Wood; Thomas J Scriba
Journal:  Am J Respir Crit Care Med       Date:  2015-03-01       Impact factor: 21.405

6.  Comparing QuantiFERON-TB Gold Plus with Other Tests To Diagnose Mycobacterium tuberculosis Infection.

Authors:  Thara K Venkatappa; Rose Punnoose; Dolly J Katz; Michael P Higgins; Niaz Banaei; Edward A Graviss; Robert W Belknap; Christine S Ho
Journal:  J Clin Microbiol       Date:  2019-10-23       Impact factor: 5.948

Review 7.  Update in Tuberculosis/Pulmonary Infections 2015.

Authors:  Serena P Koenig; Jennifer Furin
Journal:  Am J Respir Crit Care Med       Date:  2016-07-15       Impact factor: 21.405

Review 8.  Reproducibility of interferon gamma (IFN-γ) release Assays. A systematic review.

Authors:  Saloua Tagmouti; Madeline Slater; Andrea Benedetti; Sandra V Kik; Niaz Banaei; Adithya Cattamanchi; John Metcalfe; David Dowdy; Richard van Zyl Smit; Nandini Dendukuri; Madhukar Pai; Claudia Denkinger
Journal:  Ann Am Thorac Soc       Date:  2014-10

Review 9.  Gamma interferon release assays for detection of Mycobacterium tuberculosis infection.

Authors:  Madhukar Pai; Claudia M Denkinger; Sandra V Kik; Molebogeng X Rangaka; Alice Zwerling; Olivia Oxlade; John Z Metcalfe; Adithya Cattamanchi; David W Dowdy; Keertan Dheda; Niaz Banaei
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

10.  Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube Interferon Gamma Release Assays in Patients at Risk for Tuberculosis and in Health Care Workers.

Authors:  Elitza S Theel; Heather Hilgart; Margaret Breen-Lyles; Kevin McCoy; Rhiannon Flury; Laura E Breeher; John Wilson; Irene G Sia; Jennifer A Whitaker; Jeremy Clain; Timothy R Aksamit; Patricio Escalante
Journal:  J Clin Microbiol       Date:  2018-06-25       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.